Complement Deficiencies (CD) – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030


 Complement deficiencies cause susceptibility not only to bacterial infection but also to autoimmune disease. Genetically determined MBL deficiencies are observed in autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Observation of the low concentrations of MBL and other complement proteins (e.g., C1q, C1r, C4) and poor complement system activation are also characteristic of inactive SLE. Complement activation almost inevitably results in tissue destruction, as seen in rheumatic diseases such as SLE, RA, vasculitis, and antiphospholipid antibody syndrome. Interest in complement in inflammatory disease has led to the development of pharmacologic complement inhibitors such as eculizumab, a humanized monoclonal anti-C5 antibody approved for paroxysmal nocturnal hemoglobinuria. Inflammatory conditions also result from hereditary or acquired deficiencies of complement regulatory proteins. For example, lack of the C1q inhibitor protein leads to undue complement activity under metabolic stress and the development of intermittent and potentially life-threatening angioedema.

 

The estimated C2 deficiency is the most common complement deficiency in the USA, with frequency estimates of 0.5 to 1 in 10,000 for homozygous C2-deficient patients. Complement deficiencies cause susceptibility not only to bacterial infection but also to autoimmune disease. Patients with specific complement deficiencies are prone to SLE; lupus develops in approximately 90% of C1q-null, 75% of C4-null, and up to 30% of C2-null individuals.

 

The competitive landscape includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Complement Deficiencies (CD) across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Complement Deficiencies (CD) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Complement Deficiencies (CD) – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          rMenB+OMV     Novartis            Phase 3

2          CSL312            CSL Behring     Phase 3

3          BMN 331          BioMarin Pharmaceutical           Phase 1/2

4          NTLA-2002       Intellia Therapeutics      Phase 1/2

5          Berotralstat       BioCryst Pharmaceuticals          Phase 3

6          PHA-022121     Pharvaris Netherlands B.V.        Phase 2

7          KVD824            KalVista Pharmaceuticals, Ltd.   Phase 2

8          GNR-038          AO GENERIUM Phase 1

9          Donidalorsen     Ionis Pharmaceuticals, Inc.        Phase 3

10        rhC1INH           Pharming Technologies B.V.      Phase 2

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Herpes simplex virus (HSV) causes an infection that affects the external genitalia, anal region, mucosal surfaces, and skin in other body parts. Herpes simplex virus is a ubiquitous, host-adapted pathogen that causes various disease states. There are two types of HSV with two distinct DNA viruses, type 1 (HSV-1) and type 2 (HSV-2). Both the types are closely related but differ epidemiologically. HSV-1 is traditionally associated with orofacial disease by affecting the mouth and lips with fever blisters and cold sores, whereas HSV-2 is associated traditionally with genital disease infecting genitals and rectum area with sores and is classified as STD (sexually transmitted disease). As HSV-1 is associated with genital infections more often than HSV-2, lesion location is not necessarily of viral type. HSV can spread through direct contact. Almost 80% of Herpes simplex infections are asymptomatic, while symptomatic infections can be characterized by significant morbidity and recurrenc...
Read more

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
Thelansis’s “HR+/HER2- Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential HR+/HER2- Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of HR+/HER2- Breast Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs. HR+/HER2- Breast Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model,...
Read more